1, Simiao Road, Biomedical Base,
102600 Daxing District Beijing
+86 10 5961 3600
+86 10 5961 3655
Beijing Minhai Biotechnology Co., Ltd established in 2004, is the wholly-owned subsidiary of Shenzhen KangTai Biological Products Co. Ltd (SKTB), focusing on developing, manufacturing and marketing innovative vaccines for human use.
The goal of the company is innovation and timely development of new vaccines; to strengthen cooperation and actively participate in international competition, and eventually become a national first-class, based on international collaborations, to become one of the most competitive suppliers of vaccine in China.
Nowadays, the company has successfully developed vaccines against Hepatitis B, Hib, DTaP-Hib and measles-rubella (MR) vaccines. Meanwhile, the company globally collaborates with Merck on Hepatitis B vaccine, with SanofiPasteur on Rabies vaccine and with National Institute of Health on Rotavirus vaccine.
DCVMN is a voluntary public health driven alliance of vaccine
manufacturers from developing countries that aims to make a consistent supply of high quality vaccines that are accessible to protect people against
known and emerging infectious diseases globally.